Amyotrophic Lateral Sclerosis A route to larger CNS markets?

Amyotrophic lateral sclerosis (ALS) is an orphan neurodegenerative disease which effects less than twenty thousand people across the seven major markets. Nevertheless, ALS is set to provide a platform for drugs for use in more widespread conditions such as Parkinson’s Disease (PD) or Alzheimer’s Disease (AD). 

Scope

Epidemiology and prevalence data 

Current treatment and unmet market needs 

Analysis of trial data, the therapeutic potential of current and future drugs and drug classes 

Analysis of key issues in the ALS and orphan disease market supported by key opinion leader interviews 

Report Highlights

ALS is one of many orphan diseases in the CNS arena. If significant return of investment is to be realized in this market, both existing and future players must address the lack of disease awareness amongst physicians. 

Currently the only prescription drug approved for ALS is Aventis’ Rilutek (riluzole). Despite the fact that, many physicians doubt its true therapeutic value, Rilutek sales topped $100m in 2002. This demonstrates the scope for commercial opportunities which can be further increased by seeking approval for lucrative indications such as AD or PD. 

Reasons to Purchase

Assess the ALS patient potential 

Identify the key unmet needs and diagnostic tools, which would highlight novel targets 

Review the therapeutic and commercial potential of drugs and compounds in clinical trials based on ALS expert opinion and trial data 

Publisher: Datamonitor CNS Central Nervous System Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS.html#a215